论文部分内容阅读
目的评估氨溴特罗口服液在临床上用于治疗支气管炎患儿的咳嗽、痰液黏稠、排痰困难、哮鸣音等临床表现的疗效及安全性。方法117例8个月至10.5岁患急性支气管炎、支气管炎伴喘息儿童,随机分为治疗组(氨溴特罗口服液)和对照组(盐酸氨溴索糖浆)。观察两组治疗前、治疗后1、3、5d咳嗽、痰液黏稠、排痰困难、哮鸣音评分及综合评分变化。结果治疗组、对照组治疗后咳嗽、痰液黏稠、排痰困难、哮鸣音均较治疗前明显减轻(P<0.05);治疗组治疗1、3、5d后缓解咳嗽症状、排痰困难症状、哮鸣音的有效率及缩短上述表现持续时间均优于对照组(P<0.05);在减少痰量与痰液黏稠持续时间上的疗效两组无显著性差异(P>0.05);治疗组治疗5d后呼吸道症状改善的总有效率高于对照组。结论氨溴特罗口服液对于改善支气管炎患儿的咳嗽、痰液黏稠、排痰困难、喘息等临床症状疗效显著。
Objective To evaluate the efficacy and safety of ambroxol oral solution in the clinical treatment of children with bronchitis cough, sputum viscosity, expectoration difficulties, wheeze and other clinical manifestations of the efficacy and safety. Methods A total of 117 acute bronchitis and bronchitis patients with wheeze aged 8 months to 10.5 years were randomly divided into treatment group (ambroxol oral solution) and control group (ambroxol hydrochloride syrup). The two groups before treatment, 1,3,5 d after treatment, cough, sputum viscosity, expectoration difficulties, wheeze score and comprehensive score changes. Results After treatment, the cough, viscous sputum, difficulty in expectoration and wheeze of the treatment group and the control group were significantly reduced compared with those before treatment (P <0.05). The treatment group relieved the symptoms of cough, expectoration difficulty (P <0.05). There was no significant difference between the two groups in reducing the volume of sputum and the viscous duration of sputum (P> 0.05). Treatment The total effective rate of respiratory symptom improvement after 5 days of treatment was higher than that of control group. Conclusions Abruzone oral liquid has significant curative effect on clinical symptoms such as cough, viscous sputum, expectoration difficulty and wheezing in children with bronchitis.